Targeting specific gene by alkylating pyrrole-imidazole polyamides. 2008

Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
Department of Chemistry, Graduate School of Science, Kyoto University, Kyoto, 606-8502, Japan.

Targeting specific genes or gene products by small molecules is novel approach of cancer chemotherapy. We have developed sequence-specific DNA alkylating agents, conjugates between pyrrole (Py)-imidazole (Im) polyamides and 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H benz[e]indole (seco-CBI) with an indole linker. These compounds efficiently alkylate DNA at a targeted sequence and inhibit gene expression caused by alkylation at template strand of coding region. Recently, histone H4c gene could be targeted by polyamide-chlorambucil (Chl) conjugates. Thus, we designed and synthesized polyamide seco-CBI conjugates 1-5 targeting histone H4c coding sequence. High resolution denaturing polyacrylamide gel electrophoresis (PAGE) showed polyamide seco-CBI conjugates alkylated at the histone H4c coding sequence.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D009757 Nylons Polymers where the main polymer chain comprises recurring amide groups. These compounds are generally formed from combinations of diamines, diacids, and amino acids and yield fibers, sheeting, or extruded forms used in textiles, gels, filters, sutures, contact lenses, and other biomaterials. Polyamides,Dermalon,Ethilon,Nylon,Polyamide,Supramid,Dermalons,Ethilons,Supramids
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D006657 Histones Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. Histone,Histone H1,Histone H1(s),Histone H2a,Histone H2b,Histone H3,Histone H3.3,Histone H4,Histone H5,Histone H7
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating
D020868 Gene Silencing Interruption or suppression of the expression of a gene at transcriptional or translational levels. Gene Inactivation,Inactivation, Gene,Silencing, Gene

Related Publications

Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
April 2004, Journal of the American Chemical Society,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
January 2021, PloS one,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
March 2010, Anti-cancer drugs,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
December 2006, Accounts of chemical research,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
January 2003, Nucleic acids research. Supplement (2001),
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
May 2021, Chembiochem : a European journal of chemical biology,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
January 2004, Nucleic acids symposium series (2004),
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
July 2019, Advanced drug delivery reviews,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
June 2001, The EMBO journal,
Masafumi Minoshima, and James Chou, and Sophie Lefebvre, and Toshikazu Bando, and Ken-ichi Shinohara, and Joel M Gottesfeld, and Hiroshi Sugiyama
January 2006, Nucleic acids symposium series (2004),
Copied contents to your clipboard!